Summary

The clinical trial protocol NASH-001, designated under Trial number 2024-512345, is a pivotal phase 3 investigation evaluating the efficacy of AZD0292 in treating melanoma patients. This study, sponsored by Pfizer and conducted by Cancer Trials in Poland, focuses specifically on the survival benefit of the drug in patients with diabetes mellitus. The trial protocol code identifies this investigation as part of the broader MELANOMA trial series, which is designed to determine whether AZD0292 achieves the same survival results as the standard-of-care treatment while avoiding the severe side effects often associated with those therapies. Researchers aim to provide new insights into how this specific medication manages cancer in this at-risk demographic.

Title

Clinical Trials Search - CTIS.eu

Description

Clinical Trials Search - CTIS.eu

Keywords

search, trials, cancer, condition, number, sponsor, protocol, title, product, filters, trial, field, fields, country, endpoint, sort, first

NS Lookup

A 172.67.169.15, A 104.21.27.76

Dates

Created 2026-04-13

Updated 2026-04-13

Summarized None